Participated · Series A · Aug 2026

Moment builds payments infrastructure and solutions aimed at serving markets across Africa. The company framed the $22 million Series A close as a major milestone in its growth journey. Moment has attracted investors including AlphaCode Venture Partners, General Catalyst, MultiChoice Group and CANAL+ Group. Public communications from the team emphasize continued focus on expansion after the financing. The articles do not provide revenue, user metrics, founding year, or location details.

Led · Series A · Nov 2025

SeamlessHR operates in the human-resources technology vertical, providing digital tools and services for HR management. The company raised a $10 million Series A round in 2022, signalling strong investor interest. It has now secured an additional $9 million Series A extension from the Gates Foundation and Helios Digital Ventures. According to sources close to the firm, the fresh capital will be channelled toward accelerating expansion across Africa, a strategy that may include strategic acquisitions. In line with this plan, SeamlessHR reportedly held talks last year to acquire another HR tech startup in Nigeria. No revenue, user, or profitability metrics were disclosed in the articles.

Participated · Series A · Oct 2025

Founded in 2023 by fintech veterans Simon Vans-Colina, Salim Dhanani, and Dmitry Bocharov, Pave Bank delivers both traditional and programmable banking rails through APIs and smart-contract infrastructure. Its platform enables businesses to automate payments, transfers, and treasury functions while seamlessly handling fiat and digital-asset transactions. Headquartered in Singapore with a Georgian banking licence and a London office, the company positions itself at the intersection of regulated banking and blockchain technology. Management intends to expand operations into the United Arab Emirates, Hong Kong, and the European Economic Area to reach a wider enterprise customer base. Since launch, Pave Bank has secured roughly $45 million in total funding, underscoring investor confidence in its vision of programmable finance. The fresh capital will be deployed to deepen product development, obtain additional regulatory approvals, and scale geographic coverage.

Participated · Series A · May 2025

Conduit is a cross-border payments platform powered by stablecoins that integrates stablecoins, USD and local currencies across bank and blockchain rails. Its single-API network connects banks, local payment systems and blockchains to settle transactions in seconds via real-time rails including SWIFT, ACH, FedWire and local systems in markets such as Mexico, Brazil, Colombia, China, Hong Kong, Nigeria and Kenya. The company reported transaction volumes grew 16x in 2024, surpassing $10 billion in annualized payment volume; it has 57 employees, serves more than 100 clients and experienced 105% year-over-year client growth. To date Conduit says it has saved clients over 60,000 hours in settlement time and generated fee savings of more than $55 million. The platform combines crypto-native infrastructure with traditional finance and includes integrated AML, sanctions screening and transaction monitoring. Conduit plans to expand further into Asia, strengthen its footprint in Mexico and add more fiat and digital currencies to its rails. Conduit provides a B2B cross-border payments platform that lets businesses pay U.S. dollars directly to bank accounts via ACH or SWIFT, even without a U.S. entity, and off-ramp stablecoins into local currencies where needed. The company pivoted from a crypto/DeFi focus to traditional finance after the 2022 crypto downturn and launched its B2B payments product in Latin America in August 2023. Conduit partners with local banks across its markets and leverages technology to speed payouts, earning revenue on the currency spread while assuring transparency for recipients. The fintech serves more than 50 direct clients, primarily import/export businesses, payroll services and other cross-border platforms. Since the pivot its annualized transaction volume has grown to over $5 billion, with 20% of volume from Kenya and Nigeria and a 25% month-on-month revenue increase across both regions. Management plans imminent expansion across additional African markets (including Ghana and South Africa) and into Asia, and is hiring a regional team led by Eric Wainaina. Conduit aims to break even and achieve profitability before the end of the year. Conduit builds a set of APIs that let developers and financial firms plug their products into decentralized finance, handling stablecoin conversion, ledgering and rate calculations. It offers two core solutions: a growth earnings account for neobank customers and a corporate treasury product for companies. The company emphasizes being regulated and compliant to reduce compliance burdens for clients. Conduit’s customers include neobanks and small cryptocurrency exchanges, with its largest clients in Canada and Brazil, and it launched its product initially in Canada. The company plans to triple its fully remote headcount over the next year across North America and Latin America, hiring engineering, sales and compliance staff. Regulatory uncertainty from the SEC has slowed its U.S. expansion, but Conduit is targeting entry into the U.S. and Europe next.

Participated · Equity · Mar 2025

Galatea Bio is a Miami-based, AI-driven genomic research and clinical genetic testing company that provides precision medicine through AI-enabled data analytics. Founded in 2021 by Carlos D. Bustamante, Ph.D., the company focuses on large-scale patient populations enriched in non-European ancestry and integrates clinical genomics with a proprietary biobank. It uses AI-enabled algorithms to accelerate biomarker and drug-target discovery, enhance clinical diagnostics, and support biopharma partnerships. In March 2025 Galatea raised $25M in funding from a syndicate of investors. The company plans to use the proceeds to expand its clinico-genomics platform to integrate multi-modal data and AI-driven applications to refine genetic risk analysis for Mendelian and complex diseases, enable biomarker discovery, and optimize clinical trials.